Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a stricter setting on an artificial pancreas improve blood sugar control?

NCT ID NCT06466967

Disease control Sponsor: Castilla-La Mancha Health Service Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using a very tight glucose target (80-99 mg/dL) in an advanced hybrid closed-loop insulin pump (CamAPS FX) improves blood sugar control in adults with type 1 diabetes who had poor control. Forty participants who previously used multiple daily injections or other pumps were switched to this system. The main goal was to see if the time spent in the ideal blood sugar range (70-180 mg/dL) increased.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Advanced hybrid closed-loop system (CamAPS FX with Ypsopump) programmed to a tight glucose target (80-99 mg/dL)
What this could lead to
If successful, this could show that a stricter glucose target in an automated insulin pump helps people with type 1 diabetes achieve better blood sugar control and reduce complications.
What could go wrong
This is a small, completed study (40 people) without long-term follow-up. Results may not apply to everyone, and tighter targets could increase the risk of low blood sugar (hypoglycemia).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Jun 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with type 1 diabetes and poor prior glycemic control, regardless previous treatment, attended in the Public Health System of Castilla-La Mancha in the Health Area of the Ciudad Real General University Hospital

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with type 1 diabetes. * Age greater than or equal to 18 years. * HbA1c \> 7% (previous poor glycemic control condition). * Prior treatment with MDI or aHCL. Exclusion Criteria: * Other types of diabetes. * Pregnancy or pre-conception control. * Uncontrolled psychiatric disease. * Current or previous treatment with CamAPS-Ypsopump. * No glucometric data available during the periods under study. * History of severe hypoglycemia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

Contacts and locations

Locations

  • Ciudad Real General University Hospital

    Ciudad Real, 13005, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.